Citadel Advisors
BIB icon

Citadel Advisors’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Citadel Advisors’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$620K Buy
+7,611
New +$631K ﹤0.01% 8770
2025
Q4 		– Sell
-5,158
Closed -$381K – 12686
2025
Q3 		$307K Buy
+5,158
New +$278K ﹤0.01% 10316
2025
Q2 		– Sell
-10,766
Closed -$519K – 12600
2025
Q1 		$519K Buy
10,766
+4,982
+86% +$267K ﹤0.01% 8391
2024
Q4 		$293K Buy
5,784
+3,892
+206% +$231K ﹤0.01% 9702
2024
Q3 		$121K Sell
1,892
-7,080
-79% -$457K ﹤0.01% 10870
2024
Q2 		$532K Buy
+8,972
New +$496K ﹤0.01% 7927
2024
Q1 		– Sell
-25,776
Closed -$1.49M – 14568
2023
Q4 		$1.47M Buy
25,776
+13,765
+115% +$645K ﹤0.01% 5931
2023
Q3 		$576K Buy
12,011
+3,835
+47% +$197K ﹤0.01% 7749
2023
Q2 		$425K Sell
8,176
-415
-5% -$22.9K ﹤0.01% 8295
2023
Q1 		$465K Sell
8,591
-3,003
-26% -$169K ﹤0.01% 8462
2022
Q4 		$669K Buy
+11,594
New +$653K ﹤0.01% 7641
2022
Q3 		– Sell
-50,233
Closed -$2.68M – 12614
2022
Q2 		$2.43M Buy
50,233
+33,117
+193% +$1.68M ﹤0.01% 5168
2022
Q1 		$1.06M Sell
17,116
-14,775
-46% -$907K ﹤0.01% 7547
2021
Q4 		$2.59M Buy
31,891
+29,077
+1,033% +$2.49M ﹤0.01% 5639
2021
Q3 		$267K Sell
2,814
-12,871
-82% -$1.3M ﹤0.01% 11321
2021
Q2 		$1.55M Buy
15,685
+1,466
+10% +$128K ﹤0.01% 7247
2021
Q1 		$1.19M Sell
14,219
-6,751
-32% -$637K ﹤0.01% 7667
2020
Q4 		$1.81M Sell
20,970
-4,159
-17% -$322K ﹤0.01% 5535
2020
Q3 		$1.76M Buy
25,129
+18,355
+271% +$1.3M ﹤0.01% 4951
2020
Q2 		$491K Sell
6,774
-6,741
-50% -$430K ﹤0.01% 7101
2020
Q1 		$625K Sell
13,515
-9,241
-41% -$515K ﹤0.01% 6121
2019
Q4 		$1.41M Buy
22,756
+8,856
+64% +$472K ﹤0.01% 4988
2019
Q3 		$591K Sell
13,900
-3,757
-21% -$178K ﹤0.01% 6480
2019
Q2 		$915K Sell
17,657
-81,192
-82% -$4.04M ﹤0.01% 5828
2019
Q1 		$5.48M Sell
98,849
-23,972
-20% -$1.29M ﹤0.01% 2872
2018
Q4 		$5.17M Buy
122,821
+15,820
+15% +$825K ﹤0.01% 2733
2018
Q3 		$7.45M Buy
107,001
+49,525
+86% +$3.24M ﹤0.01% 2489
2018
Q2 		$3.29M Buy
57,476
+7,850
+16% +$428K ﹤0.01% 3340
2018
Q1 		$2.73M Buy
49,626
+20,226
+69% +$1.21M ﹤0.01% 3262
2017
Q4 		$1.65M Buy
29,400
+14,300
+95% +$807K ﹤0.01% 3909
2017
Q3 		$925K Buy
15,100
+7,600
+101% +$432K ﹤0.01% 4425
2017
Q2 		$401K Buy
+7,500
New +$366K ﹤0.01% 5446
2016
Q3 		– Sell
-33,894
Closed -$1.61M – 7233
2016
Q2 		$1.32M Buy
33,894
+24,744
+270% +$1.07M ﹤0.01% 3233
2016
Q1 		$374K Sell
9,150
-66,862
-88% -$2.96M ﹤0.01% 4809
2015
Q4 		$5.43M Buy
76,012
+11,548
+18% +$772K 0.01% 1736
2015
Q3 		$3.76M Buy
64,464
+9,900
+18% +$844K ﹤0.01% 2229
2015
Q2 		$4.93M Buy
54,564
+8,730
+19% +$751K ﹤0.01% 2084
2015
Q1 		$3.63M Buy
45,834
+6,276
+16% +$465K ﹤0.01% 2376
2014
Q4 		$2.48M Buy
39,558
+5,438
+16% +$319K ﹤0.01% 2665
2014
Q3 		$1.77M Buy
34,120
+16,286
+91% +$789K ﹤0.01% 2987
2014
Q2 		$828K Buy
+17,834
New +$704K ﹤0.01% 3745

Other funds holding BIB

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
KFS
Kaizen Financial Strategies Campbell, California $308M AUM 41.73% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return
CAG
Csenge Advisory Group Clearwater, Florida $2.18B AUM 16.73% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.79B AUM 27.94% 1-Year Est. Return

Citadel Advisors's BIB Position: Q1 2026 in Review

Citadel Advisors opened a new position in ProShares Ultra NASDAQ Biotechnology (BIB) in Q1 2026: 7,611 shares worth $620K. The stake represents ﹤0.01% of the portfolio and ranks #8770 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in BIB as recently as Q3 2025.

Citadel Advisors first reported a position in BIB in Q2 2014 and has held it in 41 quarters since. The position peaked at $7.45M in Q3 2018. 23 funds tracked by Wall St. Rank hold BIB as of Q1 2026.

  • Citadel Advisors held 7,611 shares of ProShares Ultra NASDAQ Biotechnology worth $620K as of Q1 2026.
  • ProShares Ultra NASDAQ Biotechnology was a new Citadel Advisors position in Q1 2026.
  • ProShares Ultra NASDAQ Biotechnology made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8770 holding.
  • Citadel Advisors first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2014 and has held it in 41 quarters since.
  • Citadel Advisors's ProShares Ultra NASDAQ Biotechnology position peaked at $7.45M in Q3 2018.
  • 23 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.